| Biologic Agent | %RS | Source | |
|---|---|---|---|
| Abatacept after IR to anti-TNF therapy | Induction -Month 12 | 11.1% | ATTAIN + LTE study (Genovese 2007) |
| Maintenance | |||
| Month 18 | 13.9% | ATTAIN + LTE study (Genovese 2007) | |
| Month 24 | 17.1% | ATTAIN + LTE study (Genovese 2007) | |
| Anti-TNF agents | Induction - Month 18 | 4% | REACT trial (Bombardieri 2007) |
| Maintenance - Month 24 | 14.4% | ATTAIN reanalysis afterIR to 2 anti-TNF agents | |
| Rituximab after IR to anti-TNF therapy | Induction -Month 12 | 6% | REFLEX + LTE study (Keystone 2007) |
| Maintenance | |||
| Month 18 | 13% | REFLEX + LTE study (Keystone 2007) | |
| Month 24 | 12% | Keystone (EULAR 2007) | |
| DMARDS | Month 24 | 1% | Clinical experts opinion |